Can anything be done to mitigate the toxicity of PD-1/PD-L1 inhibition in myeloma?Chapter 3
In this segment, Dr Lesokhin discusses the management of toxicity related to PD-1 blockade in myeloma, including the possibility of re-challenge.
In this segment, Dr Lesokhin discusses new and emerging classes of drugs likely to transform treatment for patients with myeloma.
PD-1 inhibition is noted as very promising for myeloma, though clinical trials haven’t shown a promising ORR. Why do you think this is?
In this segment, Dr Lesokhin discusses the potential of checkpoint inhibition for multiple myeloma.
In this segment, Dr Lesokhin discusses how CAR-T cell therapy may be used in patients with multiple myeloma.